Evaluation of 3,3′-Diindolylmethane with Gardasil Quadrivalent HPV Vaccine in K14-HPV16-Transgenic Mice Cervical Histology

被引:0
|
作者
Sepkovic, Daniel W. [1 ]
Pagan, Doris V. [1 ]
Stein, Johann [1 ]
Carlisle, Antoine D. [1 ]
Ksieski, H. Barbara [1 ]
Auborn, Karen [2 ]
Nyirenda, Themba [1 ]
Bradlow, H. Leon [1 ]
机构
[1] Hackensack Univ, Med Center, David & Alice Jurist Inst Res, Hackensack, NJ USA
[2] North Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA
来源
IN VIVO | 2013年 / 27卷 / 03期
关键词
3,3 '-Diindolylmethane (DIM); Gardasil Quadrivalent HPV vaccine; cervical intraepithelial neoplasia (CIN); human papilloma virus (HPV); BREAST-CANCER CELLS; HUMAN-PAPILLOMAVIRUS ONCOPROTEINS; TYPE-16 TRANSGENIC MICE; ESTROGEN METABOLISM; MOUSE MODEL; IN-VITRO; INDOLE-3-CARBINOL; CARCINOGENESIS; GENE; PAPILLOMATOSIS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The effects of 3,3'-diindolylmethane (DIM) together with the Gardasil vaccine on cervical histology were evaluated using the K14-HPV16-transgenic mouse model. The possibility that DIM could enhance the efficacy of this preventive vaccine in this model was explored. Materials and Methods: Transgenic mice were given 1000 mg/kg of DIM in the diet for 28 weeks. The mice were injected with Gardasil Quadrivalent HPV vaccine. Some mice were sacrificed at 28 weeks. Other groups were removed from the DIM diet after 28 weeks to a diet with no DIM for either 4 or 8 weeks. Results: Cervical histology indicated that a high percentage of transgenic mice fed DIM and vaccinated with Gardasil manifested normal cervical epitheliums at 4 weeks after DIM discontinuation. Conclusion: Vaccination pre-supplemented with DIM may provide with a window of protection of at least four weeks in this transgenic model. However, extrapolation to the effect in humans is beyond the limited scope of the histological data presented here.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 42 条
  • [21] A Role for MicroRNA-155 Expression in Microenvironment Associated to HPV-Induced Carcinogenesis in K14-HPV16 Transgenic Mice (vol 10, e0116868, 2015)
    Paiva, I
    da Costa, Gil R. M.
    Ribeiro, J.
    Sousa, H.
    Bastos, M.
    Rocha, A. F. C.
    [J]. PLOS ONE, 2015, 10 (07):
  • [22] Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice
    Arbeit, JM
    Olson, DC
    Hanahan, D
    [J]. ONCOGENE, 1996, 13 (09) : 1847 - 1857
  • [23] Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
    Sharma, Hitt
    Parekh, Sameer
    Pujari, Pramod
    Shewale, Sunil
    Desai, Shivani
    Bhatla, Neerja
    Joshi, Smita
    Pimple, Sharmila
    Kawade, Anand
    Balasubramani, Latha
    Thomas, Anitha
    Suri, Vanita
    Lalwani, Sanjay
    Uday, Rajini
    Kamath, Veena
    Mandal, Ranajit
    Rajeswar, A.
    Peedicayil, Abraham
    Poli, Usha Rani
    Banerjee, Dipanwita
    Sankaranarayanan, Rengaswamy
    Basu, Partha
    Muwonge, Richard
    Gairola, Sunil
    Dogar, Vikas
    Rao, Harish
    Shaligram, Umesh
    [J]. LANCET ONCOLOGY, 2023, 24 (12): : 1321 - 1333
  • [24] HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women
    Budenholzer, Brian
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 157 (02)
  • [25] Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes
    Hernandez-Avila, Mauricio
    Torres-Ibarra, Leticia
    Stanley, Margaret
    Salmeron, Jorge
    Cruz-Valdez, Aurelio
    Munoz, Nubia
    Herrero, Rolando
    Villasenor-Ruiz, Ignacio F.
    Lazcano-Ponce, Eduardo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (01) : 30 - 38
  • [26] Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice
    SmithMcCune, K
    Zhu, YH
    Hanahan, D
    Arbeit, J
    [J]. CANCER RESEARCH, 1997, 57 (07) : 1294 - 1300
  • [27] Magnetic Resonance Imaging Defines Cervicovaginal Anatomy, Cancer, and VEGF Trap Antiangiogenic Efficacy in Estrogen-Treated K14-HPV16 Transgenic Mice
    Garbow, Joel R.
    Santeford, Andrea C.
    Anderson, Jeff R.
    Engelbach, John A.
    Arbeit, Jeffrey M.
    [J]. CANCER RESEARCH, 2009, 69 (20) : 7945 - 7952
  • [28] Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?
    Kang, Woo Dae
    Choi, Ho Sun
    Kim, Seok Mo
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 264 - 268
  • [30] Prophylactic use of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VDP) vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) risk
    Ault, Kevin
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 54 - 55